Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 181 to 192 of 201 entries
Sorted by: Best Match Show Resources per page
Automated digital design for 3D-printed individualized therapies.

International journal of pharmaceutics

Eleftheriadis GK, Kantarelis E, Monou PK, Andriotis EG, Bouropoulos N, Tzimtzimis EK, Tzetzis D, Rantanen J, Fatouros DG.
PMID: 33662466
Int J Pharm. 2021 Apr 15;599:120437. doi: 10.1016/j.ijpharm.2021.120437. Epub 2021 Mar 01.

Customization of pharmaceutical products is a central requirement for personalized medicines. However, the existing processing and supply chain solutions do not support such manufacturing-on-demand approaches. In order to solve this challenge, three-dimensional (3D) printing has been applied for customization...

Cite
Eleftheriadis GK, Kantarelis E, Monou PK, et al. Automated digital design for 3D-printed individualized therapies. Int J Pharm. 2021;599:120437doi: 10.1016/j.ijpharm.2021.120437.
Eleftheriadis, G. K., Kantarelis, E., Monou, P. K., Andriotis, E. G., Bouropoulos, N., Tzimtzimis, E. K., Tzetzis, D., Rantanen, J., & Fatouros, D. G. (2021). Automated digital design for 3D-printed individualized therapies. International journal of pharmaceutics, 599120437. https://doi.org/10.1016/j.ijpharm.2021.120437
Eleftheriadis, Georgios K, et al. "Automated digital design for 3D-printed individualized therapies." International journal of pharmaceutics vol. 599 (2021): 120437. doi: https://doi.org/10.1016/j.ijpharm.2021.120437
Eleftheriadis GK, Kantarelis E, Monou PK, Andriotis EG, Bouropoulos N, Tzimtzimis EK, Tzetzis D, Rantanen J, Fatouros DG. Automated digital design for 3D-printed individualized therapies. Int J Pharm. 2021 Apr 15;599:120437. doi: 10.1016/j.ijpharm.2021.120437. Epub 2021 Mar 01. PMID: 33662466.
Copy Download .nbib Format: NLM
Advanced nanomedicine and cancer: Challenges and opportunities in clinical translation.

International journal of pharmaceutics

Gonzalez-Valdivieso J, Girotti A, Schneider J, Arias FJ.
PMID: 33662472
Int J Pharm. 2021 Apr 15;599:120438. doi: 10.1016/j.ijpharm.2021.120438. Epub 2021 Mar 02.

Cancer has reached pandemic dimensions in the whole world. Although current medicine offers multiple treatment options against cancer, novel therapeutic strategies are needed due to the low specificity of chemotherapeutic drugs, undesired side effects and the presence of different...

Cite
Gonzalez-Valdivieso J, Girotti A, Schneider J, et al. Advanced nanomedicine and cancer: Challenges and opportunities in clinical translation. Int J Pharm. 2021;599:120438doi: 10.1016/j.ijpharm.2021.120438.
Gonzalez-Valdivieso, J., Girotti, A., Schneider, J., & Arias, F. J. (2021). Advanced nanomedicine and cancer: Challenges and opportunities in clinical translation. International journal of pharmaceutics, 599120438. https://doi.org/10.1016/j.ijpharm.2021.120438
Gonzalez-Valdivieso, Juan, et al. "Advanced nanomedicine and cancer: Challenges and opportunities in clinical translation." International journal of pharmaceutics vol. 599 (2021): 120438. doi: https://doi.org/10.1016/j.ijpharm.2021.120438
Gonzalez-Valdivieso J, Girotti A, Schneider J, Arias FJ. Advanced nanomedicine and cancer: Challenges and opportunities in clinical translation. Int J Pharm. 2021 Apr 15;599:120438. doi: 10.1016/j.ijpharm.2021.120438. Epub 2021 Mar 02. PMID: 33662472.
Copy Download .nbib Format: NLM
Combined cancer therapeutics-Tackling the complexity of the tumor microenvironment.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology

Roma-Rodrigues C, Raposo LR, Valente R, Fernandes AR, Baptista PV.
PMID: 33565269
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 Sep;13(5):e1704. doi: 10.1002/wnan.1704. Epub 2021 Feb 09.

Cancer treatment has yet to find a "silver bullet" capable of selectively and effectively kill tumor cells without damaging healthy cells. Nanomedicine is a promising field that can combine several moieties in one system to produce a multifaceted nanoplatform....

Cite
Roma-Rodrigues C, Raposo LR, Valente R, et al. Combined cancer therapeutics-Tackling the complexity of the tumor microenvironment. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021;13(5):e1704doi: 10.1002/wnan.1704.
Roma-Rodrigues, C., Raposo, L. R., Valente, R., Fernandes, A. R., & Baptista, P. V. (2021). Combined cancer therapeutics-Tackling the complexity of the tumor microenvironment. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology, 13(5), e1704. https://doi.org/10.1002/wnan.1704
Roma-Rodrigues, Catarina, et al. "Combined cancer therapeutics-Tackling the complexity of the tumor microenvironment." Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology vol. 13,5 (2021): e1704. doi: https://doi.org/10.1002/wnan.1704
Roma-Rodrigues C, Raposo LR, Valente R, Fernandes AR, Baptista PV. Combined cancer therapeutics-Tackling the complexity of the tumor microenvironment. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 Sep;13(5):e1704. doi: 10.1002/wnan.1704. Epub 2021 Feb 09. PMID: 33565269.
Copy Download .nbib Format: NLM
Cubosomes: Innovative Nanostructures for Drug Delivery.

Current drug delivery

Duttagupta AS, Chaudhary HM, Jadhav KR, Kadam VJ.
PMID: 25707403
Curr Drug Deliv. 2016;13(4):482-93. doi: 10.2174/1567201812666150224114751.

BACKGROUND: Some amphiphilic lipids can self-assemble to form bicontinuous cubic liquid crystalline materials in aqueous media. These cubic structures have gained considerable attention since they impart unique properties of practical interest. Cubosomes, being dispersions of an inverted type bicontinuous...

Cite
Duttagupta AS, Chaudhary HM, Jadhav KR, et al. Cubosomes: Innovative Nanostructures for Drug Delivery. Curr Drug Deliv. 2016;13(4):482-93doi: 10.2174/1567201812666150224114751.
Duttagupta, A. S., Chaudhary, H. M., Jadhav, K. R., & Kadam, V. J. (2016). Cubosomes: Innovative Nanostructures for Drug Delivery. Current drug delivery, 13(4), 482-93. https://doi.org/10.2174/1567201812666150224114751
Duttagupta, Aindrilla S, et al. "Cubosomes: Innovative Nanostructures for Drug Delivery." Current drug delivery vol. 13,4 (2016): 482-93. doi: https://doi.org/10.2174/1567201812666150224114751
Duttagupta AS, Chaudhary HM, Jadhav KR, Kadam VJ. Cubosomes: Innovative Nanostructures for Drug Delivery. Curr Drug Deliv. 2016;13(4):482-93. doi: 10.2174/1567201812666150224114751. PMID: 25707403.
Copy Download .nbib Format: NLM
Nanomedicine.

Anticancer research

[No authors listed]
PMID: 27466578
Anticancer Res. 2016 Aug;36(8):4373.

No abstract available.

Cite
Nanomedicine. Anticancer Res. 2016;36(8):4373
(2016). Nanomedicine. Anticancer research, 36(8), 4373.
"Nanomedicine." Anticancer research vol. 36,8 (2016): 4373.
Nanomedicine. Anticancer Res. 2016 Aug;36(8):4373. PMID: 27466578.
Copy Download .nbib Format: NLM
Targeted Delivery of Shear Stress-Inducible Micrornas by Nanoparticles to Prevent Vulnerable Atherosclerotic Lesions.

Methodist DeBakey cardiovascular journal

Wong WT, Ma S, Tian XY, Gonzalez AB, Ebong EE, Shen H.
PMID: 27826369
Methodist Debakey Cardiovasc J. 2016 Sep;12(3):152-156. doi: 10.14797/mdcj-12-3-152.

Atherosclerosis is a chronic inflammatory vascular wall disease, and endothelial cell dysfunction plays an important role in its development and progression. Under the influence of laminar shear stress, however, the endothelium releases homeostatic factors such as nitric oxide and...

Cite
Wong WT, Ma S, Tian XY, et al. Targeted Delivery of Shear Stress-Inducible Micrornas by Nanoparticles to Prevent Vulnerable Atherosclerotic Lesions. Methodist Debakey Cardiovasc J. 2016;12(3):152-156doi: 10.14797/mdcj-12-3-152.
Wong, W. T., Ma, S., Tian, X. Y., Gonzalez, A. B., Ebong, E. E., & Shen, H. (2016). Targeted Delivery of Shear Stress-Inducible Micrornas by Nanoparticles to Prevent Vulnerable Atherosclerotic Lesions. Methodist DeBakey cardiovascular journal, 12(3), 152-156. https://doi.org/10.14797/mdcj-12-3-152
Wong, Wing Tak, et al. "Targeted Delivery of Shear Stress-Inducible Micrornas by Nanoparticles to Prevent Vulnerable Atherosclerotic Lesions." Methodist DeBakey cardiovascular journal vol. 12,3 (2016): 152-156. doi: https://doi.org/10.14797/mdcj-12-3-152
Wong WT, Ma S, Tian XY, Gonzalez AB, Ebong EE, Shen H. Targeted Delivery of Shear Stress-Inducible Micrornas by Nanoparticles to Prevent Vulnerable Atherosclerotic Lesions. Methodist Debakey Cardiovasc J. 2016 Sep;12(3):152-156. doi: 10.14797/mdcj-12-3-152. PMID: 27826369; PMCID: PMC5098572.
Copy Download .nbib Format: NLM
Biomineralization: An Opportunity and Challenge of Nanoparticle Drug Delivery Systems for Cancer Therapy.

Advanced healthcare materials

Wang W, Liu X, Zheng X, Jin HJ, Li X.
PMID: 33043640
Adv Healthc Mater. 2020 Nov;9(22):e2001117. doi: 10.1002/adhm.202001117. Epub 2020 Oct 11.

Biomineralization is a common process in organisms to produce hard biomaterials by combining inorganic ions with biomacromolecules. Multifunctional nanoplatforms are developed based on the mechanism of biomineralization in many biomedical applications. In the past few years, biomineralization-based nanoparticle drug...

Cite
Wang W, Liu X, Zheng X, et al. Biomineralization: An Opportunity and Challenge of Nanoparticle Drug Delivery Systems for Cancer Therapy. Adv Healthc Mater. 2020;9(22):e2001117doi: 10.1002/adhm.202001117.
Wang, W., Liu, X., Zheng, X., Jin, H. J., & Li, X. (2020). Biomineralization: An Opportunity and Challenge of Nanoparticle Drug Delivery Systems for Cancer Therapy. Advanced healthcare materials, 9(22), e2001117. https://doi.org/10.1002/adhm.202001117
Wang, Weicai, et al. "Biomineralization: An Opportunity and Challenge of Nanoparticle Drug Delivery Systems for Cancer Therapy." Advanced healthcare materials vol. 9,22 (2020): e2001117. doi: https://doi.org/10.1002/adhm.202001117
Wang W, Liu X, Zheng X, Jin HJ, Li X. Biomineralization: An Opportunity and Challenge of Nanoparticle Drug Delivery Systems for Cancer Therapy. Adv Healthc Mater. 2020 Nov;9(22):e2001117. doi: 10.1002/adhm.202001117. Epub 2020 Oct 11. PMID: 33043640.
Copy Download .nbib Format: NLM
Industry News update covering July 2021.

Therapeutic delivery

Timmins P.
PMID: 34632811
Ther Deliv. 2021 Nov;12(11):757-774. doi: 10.4155/tde-2021-0061. Epub 2021 Oct 11.

No abstract available.

Cite
Timmins P. Industry News update covering July 2021. Ther Deliv. 2021;12(11):757-774doi: 10.4155/tde-2021-0061.
Timmins, P. (2021). Industry News update covering July 2021. Therapeutic delivery, 12(11), 757-774. https://doi.org/10.4155/tde-2021-0061
Timmins, Peter. "Industry News update covering July 2021." Therapeutic delivery vol. 12,11 (2021): 757-774. doi: https://doi.org/10.4155/tde-2021-0061
Timmins P. Industry News update covering July 2021. Ther Deliv. 2021 Nov;12(11):757-774. doi: 10.4155/tde-2021-0061. Epub 2021 Oct 11. PMID: 34632811.
Copy Download .nbib Format: NLM
Biogenesis of Extracellular Vesicles.

Sub-cellular biochemistry

Kang T, Atukorala I, Mathivanan S.
PMID: 33779912
Subcell Biochem. 2021;97:19-43. doi: 10.1007/978-3-030-67171-6_2.

Extracellular vesicles (EVs) refer to vesicles that are released by cells into the extracellular space. EVs mediate cell-to-cell communication via delivery of functional biomolecules between host and recipient cells. EVs can be categorised based on their mode of biogenesis...

Cite
Kang T, Atukorala I, Mathivanan S. Biogenesis of Extracellular Vesicles. Subcell Biochem. 2021;97:19-43doi: 10.1007/978-3-030-67171-6_2.
Kang, T., Atukorala, I., & Mathivanan, S. (2021). Biogenesis of Extracellular Vesicles. Sub-cellular biochemistry, 9719-43. https://doi.org/10.1007/978-3-030-67171-6_2
Kang, Taeyoung, et al. "Biogenesis of Extracellular Vesicles." Sub-cellular biochemistry vol. 97 (2021): 19-43. doi: https://doi.org/10.1007/978-3-030-67171-6_2
Kang T, Atukorala I, Mathivanan S. Biogenesis of Extracellular Vesicles. Subcell Biochem. 2021;97:19-43. doi: 10.1007/978-3-030-67171-6_2. PMID: 33779912.
Copy Download .nbib Format: NLM
Understanding and improving FDM 3D printing to fabricate high-resolution and optically transparent microfluidic devices.

Lab on a chip

Quero RF, Domingos da Silveira G, Fracassi da Silva JA, Jesus DP.
PMID: 34355724
Lab Chip. 2021 Sep 28;21(19):3715-3729. doi: 10.1039/d1lc00518a.

The fabrication of microfluidic devices through fused deposition modeling (FDM) 3D printing has faced several challenges, mainly regarding obtaining microchannels with suitable transparency and sizes. Thus, the use of this printing system to fabricate microdevices for analytical and bioanalytical...

Cite
Quero RF, Domingos da Silveira G, Fracassi da Silva JA, et al. Understanding and improving FDM 3D printing to fabricate high-resolution and optically transparent microfluidic devices. Lab Chip. 2021;21(19):3715-3729doi: 10.1039/d1lc00518a.
Quero, R. F., Domingos da Silveira, G., Fracassi da Silva, J. A., & Jesus, D. P. (2021). Understanding and improving FDM 3D printing to fabricate high-resolution and optically transparent microfluidic devices. Lab on a chip, 21(19), 3715-3729. https://doi.org/10.1039/d1lc00518a
Quero, Reverson Fernandes, et al. "Understanding and improving FDM 3D printing to fabricate high-resolution and optically transparent microfluidic devices." Lab on a chip vol. 21,19 (2021): 3715-3729. doi: https://doi.org/10.1039/d1lc00518a
Quero RF, Domingos da Silveira G, Fracassi da Silva JA, Jesus DP. Understanding and improving FDM 3D printing to fabricate high-resolution and optically transparent microfluidic devices. Lab Chip. 2021 Sep 28;21(19):3715-3729. doi: 10.1039/d1lc00518a. PMID: 34355724.
Copy Download .nbib Format: NLM
Current advances and challenges of mesenchymal stem cells-based drug delivery system and their improvements.

International journal of pharmaceutics

Su Y, Zhang T, Huang T, Gao J.
PMID: 33737099
Int J Pharm. 2021 May 01;600:120477. doi: 10.1016/j.ijpharm.2021.120477. Epub 2021 Mar 16.

Mesenchymal stem cells (MSCs) have recently emerged as a promising living carrier for targeted drug delivery. A wealth of literature has shown evidence for great advances in MSCs-based drug delivery system (MSCs-DDS) in the treatment of various diseases. Nevertheless,...

Cite
Su Y, Zhang T, Huang T, et al. Current advances and challenges of mesenchymal stem cells-based drug delivery system and their improvements. Int J Pharm. 2021;600:120477doi: 10.1016/j.ijpharm.2021.120477.
Su, Y., Zhang, T., Huang, T., & Gao, J. (2021). Current advances and challenges of mesenchymal stem cells-based drug delivery system and their improvements. International journal of pharmaceutics, 600120477. https://doi.org/10.1016/j.ijpharm.2021.120477
Su, Yuanqin, et al. "Current advances and challenges of mesenchymal stem cells-based drug delivery system and their improvements." International journal of pharmaceutics vol. 600 (2021): 120477. doi: https://doi.org/10.1016/j.ijpharm.2021.120477
Su Y, Zhang T, Huang T, Gao J. Current advances and challenges of mesenchymal stem cells-based drug delivery system and their improvements. Int J Pharm. 2021 May 01;600:120477. doi: 10.1016/j.ijpharm.2021.120477. Epub 2021 Mar 16. PMID: 33737099.
Copy Download .nbib Format: NLM
Evaluation of exosome derivatives as bio-informational reprogramming therapy for cancer.

Journal of translational medicine

Gonzalez MJ, Kweh MF, Biava PM, Olalde J, Toro AP, Goldschmidt-Clermont PJ, White IA.
PMID: 33750417
J Transl Med. 2021 Mar 09;19(1):103. doi: 10.1186/s12967-021-02768-8.

Exosomes are nanoparticle sized (100 ± 50 nm) extracellular vesicles (ECVs) that play important roles in cell-to-cell communication. They do this by utilizing their natural ability to shuttle signaling molecules across the cellular microenvironment and promote paracrine signaling. Currently,...

Cite
Gonzalez MJ, Kweh MF, Biava PM, et al. Evaluation of exosome derivatives as bio-informational reprogramming therapy for cancer. J Transl Med. 2021;19(1):103doi: 10.1186/s12967-021-02768-8.
Gonzalez, M. J., Kweh, M. F., Biava, P. M., Olalde, J., Toro, A. P., Goldschmidt-Clermont, P. J., & White, I. A. (2021). Evaluation of exosome derivatives as bio-informational reprogramming therapy for cancer. Journal of translational medicine, 19(1), 103. https://doi.org/10.1186/s12967-021-02768-8
Gonzalez, Michael J, et al. "Evaluation of exosome derivatives as bio-informational reprogramming therapy for cancer." Journal of translational medicine vol. 19,1 (2021): 103. doi: https://doi.org/10.1186/s12967-021-02768-8
Gonzalez MJ, Kweh MF, Biava PM, Olalde J, Toro AP, Goldschmidt-Clermont PJ, White IA. Evaluation of exosome derivatives as bio-informational reprogramming therapy for cancer. J Transl Med. 2021 Mar 09;19(1):103. doi: 10.1186/s12967-021-02768-8. PMID: 33750417; PMCID: PMC7944634.
Copy Download .nbib Format: NLM
Showing 181 to 192 of 201 entries